A Couple-based Gender-transformative Intervention on IPV Against Infertile Women
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Nov 6, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special program can help reduce violence against women who are struggling with infertility. It focuses on couples who are going through their first or second round of in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) due to female-factor infertility. The trial will include couples who have agreed to participate and who meet specific criteria, such as not using donated eggs or sperm and not having severe male-factor infertility. A total of 376 couples will be involved, with half receiving the intervention and the other half getting standard reproductive care.
Participants in the intervention group will attend five sessions where they will learn about gender equality and healthy relationship skills. These sessions will be led by trained professionals. The main goal is to see if this program can lower the rates of intimate partner violence (IPV) against women in the study over the past year. If you or someone you know is facing infertility challenges and is interested in this trial, it could be an opportunity to receive support while contributing to important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Couples who are undergoing their first or second IVF/ICSI cycle;
- • Couples diagnosed with female-factor infertility;
- • Couples who have signed consent.
- Exclusion Criteria:
- • Couples who receive donated oocytes, sperm, or embryos;
- • Couples diagnosed with severe male-factor infertility or unexplained infertility.
- • Couples who are undergoing Preimplantation Genetic Testing (PGT);
- • Couples who have not undergone embryo transfer within six months after oocyte retrieval;
- • Couples who have severe mental disorders;
- • Couples who withdrew from the study.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, Beijing, China
Beijing, , China
Patients applied
Trial Officials
Jie Qiao, Dr
Principal Investigator
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported